Cancer Research UK selects Medidata’s cloud-based tech

Cancer Research UK, the world’s largest charitable funder of cancer research, has selected Medidata’s clinical cloud to support the charity’s drug discovery research.

Cancer Research UK’s Centre for Drug Development (CDD) is leveraging Medidata’s cloud-based technology for electronic data capture and management with the aim of conducting faster, safer clinical trials at research institutes, universities and hospitals across the UK.

Medidata’s cloud-based platform provides us with the flexibility and scalability we need to accelerate progress across all our trials,” said Dr. Nigel Blackburn, director of Cancer Research UK’s CDD. “Having immediate access to high-quality data will ultimately help us shorten trial delivery times, reduce costs and maximise the output of studies so that we can accelerate progress and bring new treatments to cancer patients sooner.”

Using Medidata’s cloud-based data management and capture system, the CDD will make clinical data from its future trials easily accessible to researchers in real time. By providing a standardised, central system for data entry, the Medidata platform aims to improve data quality, allow clinicians to easily monitor patients’ safety and enable more insightful decision making across all CDD trials.

Stephen Nabarro, head of clinical operations, data management at Cancer Research UK’s Centre for Drug Development, told Outsourcing-Pharma.com: “Cancer Research UK chose Medidata for several reasons, including the bespoke pricing model to fit the charity’s unique needs as a funder of early phase clinical trials with a rapidly growing portfolio.

“We were impressed with the technology, including the fact that the charity will not need to provide significant support to maintain the software."

The deal comes as Medidata continues to push the boundaries of how it’s technologies are being utilized by industry. Medidata recently partnered with Garmin to track patient activity in early clinical trials. CRO (contract research organization) partnerships also doubled for the company in 2014. Cancer Research UK also announced on Wednesday that it’s linking up with the Engineering and Physical Sciences Research Council (EPSRC) to co-fund multidisciplinary research projects.